Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in chinese patients undergoing liver transplantation

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2387-2401

  Chen, Hao ^a   Gu, Zhidong ^a   Chen, Bing ^a   Mao, Huarong ^a   Zhang, Weixia ^a   Fan, Qishi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

enzyme multiplied immunoassay technique; limited sampling strategy; liver transplantation; mycophenolic acid; pharmacokinetic

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOOTSTRAPPING; CHINESE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GRAFT RECIPIENT; HUMAN; LABORATORY TEST; LIVER TRANSPLANTATION; MALE; MATHEMATICAL MODEL; MAXIMUM ALLOWABLE CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE LINEAR REGRESSION ANALYSIS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHINA; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; TIME FACTORS;

EID: 58249141457     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.017     Document Type: Article

References (36)

1. Srinivas T.R., Kaplan B., and Meier-Kriesche H.U. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 4 (2003) 2325-2345
2. Bullingham R.E., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 28 (1996) 925-929
3. Allison A.C. Mechanisms of action of mycophenolate mofetil. Lupus 14 Suppl 1 (2005) S2-S8
4. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 1 (2005) 505-526
5. Kuypers D.R., and Vanrenterghem Y.C. Tailoring immunosuppressive therapy. Nephrol Dial Transplant 17 (2002) 2051-2054
6. McDiarmid S.V. Mycophenolate mofetil in liver transplantation. Clin Transplant 10 (1996) 140-145
7. Beckebaum S., Cicinnati V.R., Klein C.G., et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: Preliminary results of an open prospective study. Transplant Proc 36 (2004) 2671-2674
8. Cantarovich M., Tzimas G.N., Barkun J., et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in longterm liver-transplant patients with renal dysfunction. Transplantation 76 (2003) 98-102
9. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672-683
10. Yamani M.H., Starling R.C., Goormastic M., et al. The impact of routine mycophenolate mofetil drug moni toring on the treatment of cardiac allograft rejection. Transplantation 69 (2000) 2326-2330
11. Tredger J.M., Brown N.W., Adams J., et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 10 (2004) 492-502
12. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
13. Chen H., Peng C., Yu Z., et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 46 (2007) 175-185
14. Hao C., Erzheng C., Anwei M., et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 13 (2007) 1684-1693
15. Brunet M., Cirera I., Martorell J., et al. Sequential determination of pharmacokinetics and pharmaco-dynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 81 (2006) 541-546
16. Jain A., Venkataramanan R., Hamad I.S., et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 41 (2001) 268-276
17. Pisupati J., Jain A., Burckart G., et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 45 (2005) 34-41
18. Mardigyan V., Tchervenkov J., Metrakos P., et al. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation. Clin Ther 27 (2005) 463-469
19. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261-266
20. Mourad M., Malaise J., Chaib Eddour D., et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47 (2001) 88-94
21. Johnson A.G., Rigby R.J., Taylor P.J., et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 66 (1999) 492-500
22. Filler G., and Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 22 (2000) 169-173
23. Pawinski T., Hale M., Korecka M., et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 48 (2002) 1497-1504
24. Oellerich M., Shipkova M., Schutz E., et al. Pharmacolkinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients [published correction appears in Ther Drug Monit. 2000;22:500]. Ther Drug Monit 22 (2000) 20-26
25. Gupta S.S., and Huang D.Y. A note on optimal subset selection procedures. Ann Stat 8 (1980) 1164-1167
26. Brendel K., Dartois C., Comets E., et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46 (2007) 221-234
27. Venkataramanan R., and Shaw L.M. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl 10 (2004) 503-505
28. Nicholls A.J. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 31 (1998) 329-333
29. Le Guellec C., Büchler M., Giraudeau B., et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 57 (2002) 805-811
30. Payen S., Zhang D., Maisin A., et al. Population pharmacokinetics of mycophenolic acid in kidney trans plant pediatric and adolescent patients. Ther Drug Monit 27 (2005) 378-388
31. Hesselink D.A., van Hest R.M., Mathot R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987-994
32. van Gelder T., Klupp J., Barten M.J., et al. Comparison of the effects of tacrolimus and cyclosporine on the pharma cokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
33. Mahmood I., and Miller R. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: A computer simulation analysis. Int J Clin Pharmacol Ther 37 (1999) 439-445
34. Ting L.S., Villeneuve E., and Ensom M.H. Beyond cyclosporine: A systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 28 (2006) 419-430
35. Efron B. Bootstrap methods: Another look at the jackknife. Ann Stat 7 (1979) 1-26
36. Takemoto S., Yamaoka K., Nishikawa M., and Takakura Y. Histogram analysis of pharmacokinetic parameters by bootstrap resampling from onepoint sampling data in animal experiments. Drug Metab Pharmacokinet 21 (2006) 458-464